Jacob Friedman - BioLine RX Director
| BLRX Stock | ILS 17.00 0.10 0.59% |
Director
Mr. Jacob Friedman serves as Director at BioLine Rx Ltd since February 8, 2007. Mr. Friedman has worked as an Analyst for Friedberg Mercantile Group Ltd since 2001 since 2007.
| Age | 43 |
| Tenure | 17 years |
| Professional Marks | MBA |
| Phone | (972) 8 642 9101 |
| Web | www.biolinerx.com |
BioLine RX Management Efficiency
The company has return on total asset (ROA) of (0.2029) % which means that it has lost $0.2029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3721) %, meaning that it generated substantial loss on money invested by shareholders. BioLine RX's management efficiency ratios could be used to measure how well BioLine RX manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Edith Lusky | Bezeq Israeli Telecommunication | 66 | |
| Ehud Mezuman | Bezeq Israeli Telecommunication | 62 | |
| Rami Nomkin | Bezeq Israeli Telecommunication | 68 | |
| Or Elovitch | Bezeq Israeli Telecommunication | 40 | |
| Dov Kotler | Bezeq Israeli Telecommunication | 60 | |
| Michal Preminger | Compugen | N/A | |
| Ruth Arnon | Compugen | 86 | |
| Haggai Herman | Bezeq Israeli Telecommunication | 51 | |
| Eran Perry | Compugen | N/A | |
| Dov Hershberg | Compugen | 74 | |
| Zeev Vurembrand | Bezeq Israeli Telecommunication | 66 | |
| Mordechai Keret | Bezeq Israeli Telecommunication | 60 | |
| JeanPierre Bizzari | Compugen | 64 | |
| Doron Turgeman | Bezeq Israeli Telecommunication | 49 | |
| Joshua Shemer | Compugen | 63 | |
| Arie Ovadia | Compugen | 67 | |
| Tali Simon | Bezeq Israeli Telecommunication | 48 | |
| David Granot | Bezeq Israeli Telecommunication | 71 | |
| Yair Aharonowitz | Compugen | 73 | |
| Orly Guy | Bezeq Israeli Telecommunication | 56 | |
| Kinneret Savitsky | Compugen | 50 | |
Management Performance
| Return On Equity | -0.37 | |||
| Return On Asset | -0.2 |
BioLine RX Leadership Team
Elected by the shareholders, the BioLine RX's board of directors comprises two types of representatives: BioLine RX inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioLine. The board's role is to monitor BioLine RX's management team and ensure that shareholders' interests are well served. BioLine RX's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioLine RX's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ella Sorani, Vice President - Development | ||
| Leah Klapper, Consultant | ||
| Avraham Molcho, External Director | ||
| CPA MBA, Chief Officer | ||
| Moshe Phillip, Vice President of Medical Affairs and Senior Clinical Advisor | ||
| Aharon Schwartz, Chairman of the Board | ||
| Mali Zeevi, Finance Director | ||
| Arnon Aharon, Vice President-Medical Affairs | ||
| Merril Gersten, Chief Scientific Officer | ||
| Holly MBA, Pres USA | ||
| Michael Anghel, Director | ||
| Raphael Hofstein, Director | ||
| CPA CPA, Chief Officer | ||
| Raziel Fried, Treasurer Director | ||
| Sandra Panem, Director | ||
| Philip Serlin, CFO, COO | ||
| Advocate Kotler, Gen Officer | ||
| John Lacey, Head Relations | ||
| Abi MD, Chief Officer | ||
| LLB BSc, Head Advisor | ||
| Abi VainsteinHaras, Vice President-Clinical & Medical Affairs | ||
| Jacob Friedman, Director | ||
| BarbaraJean Bormann, Director | ||
| Kinneret Savitsky, CEO | ||
| Jael MSc, QA RA | ||
| Liron MBA, Director Devel | ||
| Hillit Shachar, Vice President - Business Development | ||
| David Malek, Vice President - Business Development | ||
| Nurit Benjamini, External Director |
BioLine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioLine RX a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | (13.02 M) | |||
| Shares Outstanding | 922.87 M | |||
| Shares Owned By Insiders | 0.25 % | |||
| Shares Owned By Institutions | 0.10 % | |||
| Price To Book | 0.77 X | |||
| EBITDA | (25.37 M) | |||
| Net Income | (27.05 M) | |||
| Cash And Equivalents | 40.61 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioLine RX in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioLine RX's short interest history, or implied volatility extrapolated from BioLine RX options trading.
Pair Trading with BioLine RX
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioLine RX position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioLine RX will appreciate offsetting losses from the drop in the long position's value.Moving against BioLine Stock
| 0.73 | HARL | Harel Insurance Inve | PairCorr |
| 0.59 | MGDL | Migdal Insurance | PairCorr |
The ability to find closely correlated positions to BioLine RX could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioLine RX when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioLine RX - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioLine RX to buy it.
The correlation of BioLine RX is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioLine RX moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioLine RX moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioLine RX can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLine RX. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for BioLine Stock analysis
When running BioLine RX's price analysis, check to measure BioLine RX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLine RX is operating at the current time. Most of BioLine RX's value examination focuses on studying past and present price action to predict the probability of BioLine RX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLine RX's price. Additionally, you may evaluate how the addition of BioLine RX to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |